Halcyon Drugs And Formulation Profile
Key Indicators
- Authorised Capital ₹ 0.80 M
as on 10-01-2025
- Paid Up Capital ₹ 0.10 M
as on 10-01-2025
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.50 M
as on 10-01-2025
- Revenue -12.47%
(FY 2016)
- Profit -60.30%
(FY 2016)
- Ebitda -45.80%
(FY 2016)
- Net Worth -1.05%
(FY 2016)
- Total Assets 18.73%
(FY 2016)
About Halcyon Drugs And Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.80 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sujeet Sahu and Payal Sahu serve as directors at the Company.
- CIN/LLPIN
U24232UP2005PTC031018
- Company No.
031018
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Halcyon Drugs And Formulation?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujeet Sahu  | Director | 30-Nov-2005 | Current |
| Payal Sahu | Director | 10-Dec-2012 | Current |
Financial Performance of Halcyon Drugs And Formulation.
Halcyon Drugs And Formulation Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 12.47% decrease. The company also saw a substantial fall in profitability, with a 60.3% decrease in profit. The company's net worth dipped by a decrease of 1.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Halcyon Drugs And Formulation?
In 2017, Halcyon Drugs And Formulation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Convira Pharmaceuticals Private LimitedActive 12 years 11 monthsSujeet Sahu and Payal Sahu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 24 Jan 2009 | ₹1.50 M | Satisfied |
How Many Employees Work at Halcyon Drugs And Formulation?
Unlock and access historical data on people associated with Halcyon Drugs And Formulation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Halcyon Drugs And Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Halcyon Drugs And Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
